Replimune Group (REPL) awards CCO 75K options plus 50K RSUs
Rhea-AI Filing Summary
Replimune Group, Inc. disclosed that Chief Commercial Officer Christopher Sarchi received new equity awards as part of his compensation. He was granted employee stock options for 75,000 shares of common stock at an exercise price of $7.61 per share, vesting 25% on April 1, 2027 and monthly thereafter until fully vested. He also received 50,000 restricted stock units (RSUs), each representing one share of common stock, vesting 25% on May 15, 2027 and then in three approximately equal annual installments through May 15, 2030, subject to continued service. Following these awards, he directly holds 201,588 shares of common stock. These are compensation grants, not open‑market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 50,000 shares
Net Buy
2 txns
Insider
Sarchi Christopher
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 75,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 50,000 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 75,000 shares (Direct);
Common Stock — 201,588 shares (Direct)
Footnotes (2)
- F1. Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer.
- F2. 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.
Key Figures
Stock options granted: 75,000 options
Option exercise price: $7.61 per share
Option expiration: April 1, 2036
+3 more
6 metrics
Stock options granted
75,000 options
Employee stock options granted on April 1, 2026
Option exercise price
$7.61 per share
Exercise price for 75,000 employee stock options
Option expiration
April 1, 2036
Expiration date of granted stock options
RSUs granted
50,000 RSUs
Restricted stock units granted to CCO
RSU initial vesting
May 15, 2027
25% of RSUs vest on this date
Common shares after grant
201,588 shares
Direct common stock holdings after transactions
Key Terms
Employee Stock Option, restricted stock units ("RSUs"), contingent right, vest, +1 more
5 terms
Employee Stock Option financial
"Employee Stock Option (right to buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
restricted stock units ("RSUs") financial
"Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs")"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's common stock."
vest financial
"25% of the RSUs will vest on May 15, 2027 and the remainder will vest"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
settlement financial
"common stock issuable upon settlement of restricted stock units ("RSUs") granted"
Settlement is the process of completing a financial transaction, like buying or selling a stock, by transferring money and ownership between parties. It ensures that both the buyer gets the asset and the seller gets paid, making the deal official. Without settlement, the transaction wouldn't be finalized or legally recognized.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Replimune Group (REPL) report for Christopher Sarchi?
Replimune Group reported that Chief Commercial Officer Christopher Sarchi received grants of stock options and restricted stock units as compensation, not open‑market trades. He was awarded 75,000 options and 50,000 RSUs that vest over several years, subject to his continued service with the company.
How many stock options did the CCO of Replimune Group (REPL) receive and at what price?
Christopher Sarchi received 75,000 employee stock options to buy Replimune Group common stock at an exercise price of $7.61 per share. These options vest 25% on April 1, 2027, with the remaining shares vesting in 36 approximately equal monthly installments thereafter through the full term.
What are the terms of the RSU grant reported for Replimune Group (REPL) CCO?
The Form 4 shows a grant of 50,000 restricted stock units to Christopher Sarchi, each RSU representing one share of common stock. Twenty‑five percent of these RSUs vest on May 15, 2027, with the remaining units vesting in three approximately equal annual installments through May 15, 2030.
When do Christopher Sarchi’s Replimune Group (REPL) stock options expire?
The granted employee stock options to Christopher Sarchi expire on April 1, 2036. This long‑dated expiration gives him a multi‑year window to potentially exercise the options after they vest, subject to the vesting schedule and any applicable company or regulatory trading restrictions.
Are the Replimune Group (REPL) transactions open‑market buys or routine compensation?
The reported transactions are routine compensation awards, not open‑market purchases or sales. They consist of a grant of employee stock options and restricted stock units to Chief Commercial Officer Christopher Sarchi, with vesting spread over several years, contingent on his continued service with the company.